Jacobs Levy Equity Management Inc. Lowers Holdings in Kronos Bio, Inc. (NASDAQ:KRON)

Jacobs Levy Equity Management Inc. trimmed its holdings in Kronos Bio, Inc. (NASDAQ:KRON) by 26.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 300,968 shares of the company’s stock after selling 105,796 shares during the quarter. Jacobs Levy Equity Management Inc. owned 0.50% of Kronos Bio worth $286,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Peapod Lane Capital LLC purchased a new stake in shares of Kronos Bio during the 4th quarter worth about $534,000. Deltec Asset Management LLC purchased a new stake in shares of Kronos Bio during the 4th quarter worth about $190,000. Renaissance Technologies LLC boosted its stake in shares of Kronos Bio by 19.7% during the 4th quarter. Renaissance Technologies LLC now owns 1,171,808 shares of the company’s stock worth $1,113,000 after acquiring an additional 192,754 shares in the last quarter. Gilead Sciences Inc. purchased a new stake in shares of Kronos Bio during the 4th quarter worth about $179,000. Finally, Kennedy Capital Management LLC boosted its stake in shares of Kronos Bio by 8.7% during the 4th quarter. Kennedy Capital Management LLC now owns 149,251 shares of the company’s stock worth $142,000 after acquiring an additional 12,007 shares in the last quarter. 64.09% of the stock is owned by hedge funds and other institutional investors.

Kronos Bio Stock Down 3.4%

KRON stock opened at $0.68 on Monday. The company’s 50-day simple moving average is $0.82 and its 200-day simple moving average is $0.91. Kronos Bio, Inc. has a 52-week low of $0.65 and a 52-week high of $1.60. The firm has a market cap of $41.53 million, a P/E ratio of -0.48 and a beta of 1.75.

Kronos Bio (NASDAQ:KRON) last posted its earnings results on Tuesday, March 18th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.13). Kronos Bio had a negative return on equity of 64.55% and a negative net margin of 867.66%. The firm had revenue of $2.27 million for the quarter, compared to analysts’ expectations of $1.00 million. On average, analysts anticipate that Kronos Bio, Inc. will post -1.36 earnings per share for the current fiscal year.

About Kronos Bio

Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.